指南与共识生殖医学

法国IVF指南在COVID-19疫情期间的验证

Validation of the French IVF guidelines during the COVID-19 pandemic.
指南 / 共识 · Reprod Biomed Online · 2021-06-13

本研究评估法国IVF指南中的症状问卷在COVID-19疫情期间筛查接受IVF患者的充分性。研究纳入2020年6月至2021年2月计划IVF的患者,比较仅问卷组(组1)与问卷加RT-PCR组(组2)的周期取消率,并检测组1卵泡液SARS-CoV-2 RNA及随访COVID-19暴露。结果显示周期取消率组1为0%(0/214),组2为1.4%(8/577)(P=0.116),183份卵泡液样本均阴性。结论认为症状问卷筛查有效,卵泡环境无COVID-19。

要点

  • 症状问卷筛查下IVF周期取消率低(组1 0%,组2 1.4%),组间无显著差异(P=0.116)。
  • 183份卵泡液样本SARS-CoV-2 RNA均阴性,提示筛查后卵泡环境无病毒。
  • 随访171例患者中16例(93.4%)出现COVID-19症状或RT-PCR阳性,但均不在取卵前后2个月内。

核心结论

  • 症状问卷筛查对计划IVF的患者有效,与法国COVID-19 IVF指南一致。
  • 卵泡液未检出SARS-CoV-2 RNA不能排除卵泡液作为病毒储库的可能性,但筛查后卵泡环境无COVID-19。

研究设计与样本

  • 研究纳入2020年6月至2021年2月计划IVF的患者。
  • 组1(2020年6月至9月)仅完成症状问卷,组2(2020年9月后)加做SARS-CoV-2 RT-PCR。
  • 比较两组周期取消率,组1检测卵泡液SARS-CoV-2 RNA并进行周期完成后访谈。

主要发现

  • 组1周期取消率为0%(0/214),组2为1.4%(8/577),P=0.116。
  • 组1的183份卵泡液样本SARS-CoV-2 RNA均阴性。
  • 171例访谈患者中16例(93.4%)出现COVID-19症状或RT-PCR阳性,但无一在取卵前后2个月内。

关键数值与推荐

  • 所有取卵日无发热患者按法国IVF指南完成症状问卷筛查。
  • 组2患者额外接受SARS-CoV-2 RT-PCR检测。

临床怎么用

  • 在COVID-19疫情期间,可采用症状问卷筛查计划IVF的患者,以降低周期取消率。
  • 筛查后卵泡液未检出病毒RNA,为卵泡环境无COVID-19提供 reassurance。

局限性

  • 卵泡液未检出病毒RNA不能完全排除卵泡液作为病毒储库的可能性。
  • 研究为观察性设计,组间比较非随机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Is a symptom questionnaire as per the French IVF guidelines adequate for screening patients during the COVID-19 pandemic? DESIGN: Patients planning IVF from June 2020 to February 2021 were included in the study. In compliance with French IVF guidelines, all patients fever-free on the day of oocyte retrieval were screened for risk of COVID-19 by completing a symptom questionnaire after being counselled regarding the importance of a COVID-19-free medical practice. Patients with IVF planned between June and September 2020 only completed the questionnaire (group 1), while those planning IVF after September 2020 also underwent the RT-PCR test for SARS-CoV-2 RNA (group 2). Cycle cancellation rates between groups were compared. Group 1 patients consented for follicular fluid testing for SARS-CoV-2 and an interview after cycle completion to determine COVID-19 exposure during the 6 months before and after retrieval. RESULTS: Cycle cancellation rates for groups 1 and 2 were 0% (0/214) versus 1.4% (8/577), respectively, (P = 0.116). All 183 follicular fluid samples from group 1 were negative for SARS-CoV-2 RNA. Of 171 patients interviewed post-IVF, 16 (93.4%) developed COVID-19 symptoms or a positive real-time PCR (RT-PCR) RT-PCR test, but none within 2 months pre- or post-retrieval. CONCLUSIONS: These results provide reassurance that, consistent with the COVID-19 French IVF guidelines, use of a symptom questionnaire is effective in screening patients planning to undergo IVF. Failure to detect viral RNA in any follicular fluid sample does not negate the possibility that follicular fluid is a viral reservoir. However, the findings provide reassurance that the follicular environment in this study's carefully screened population was COVID-free.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Poulain M, Fossard C, Benammar A, et al. Validation of the French IVF guidelines during the COVID-19 pandemic. Reprod Biomed Online. 2021. PMID: 34274240. doi:10.1016/j.rbmo.2021.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。